Berlin, Germany
HelloBetter, founded in 2015, is a trailblazer in the digital health industry, specializing in digital therapeutics (DTx) for mental health. As a pioneer in digital mental health research, the company boasts the strongest evidence base globally, backed by 33 randomized controlled trials featured in peer-reviewed journals. This robust scientific foundation underscores its credibility in the field.
Headquartered in Germany, HelloBetter has integrated its solutions as a standard of care in the region, offering six therapy programs freely as prescription digital therapeutics (DiGA) to over 70 million people. Expanding its reach, it entered the US market in 2022 with HelloGina, a sexual wellness program. Furthermore, in 2023, their HelloBetter Panic received Breakthrough Device Designation from the FDA, reinforcing its innovative edge.
The latest funding round, totaling €6.00M from Brinc, MassMutual Ventures, HealthCap, Expon Capital, and Mutuelles Impact, positions HelloBetter well for continued growth and expansion.
